Connect Biopharma Holdings Limited · NASDAQ:CNTB
Connect Biopharma — Technical Presentation (January 2022)
23 slides from Connect Biopharma's technical presentation, Jan 5, 2022
Slide 1: Global Phase 2b Trial in Atopic Dermatitis Topline Results
Exhibit 99.2 C B P - 2 0 1 -WW001 G l o b a l P h a s e 2 b T r i a l i n A t o p i c D e r m a t i t i s T o p l i n e R e s u l t s NEXT-GENERATION THERAPEUTICS FOR T CELL-DRIVEN INFLAMMATORY DISEASES th Conference Call - 5 January 2022
Slide 2: Forward-Looking Statements
2 2 Forward-Looking Statements • This presentation regarding Connect Biopharma Holdings Limited ( Connect, we, us or our ) has been prepared solely for informational purposes. • Certain information contained in this presentation relates to, or is based on, studies, publications, surveys and other da
Slide 3: WW001 – Summary – Primary Analyses
WW001 – Summary – Primary Analyses 3 3 A Phase 2b trial evaluating CBP-201 in adult patients with moderate-to-severe Atopic Dermatitis (AD) CBP-201 met primary endpoint & multiple key secondary endpoints in WW001 • CBP-201, a novel, human monoclonal antibody targeting IL-4Ra, a common subunit for IL
Slide 4: WW001 – Summary – Additional Analyses
4 4 WW001 – Summary – Additional Analyses CBP-201 300mg Q2W and Q4W 300mg appear at least comparable with potential for differentiation Not a head-to-head trial. Differences exist between trial designs and subject characteristics and caution should be exercised when comparing data across trials • WW
Slide 5: WW001 - Global Phase 2b AD Trial Design
5 5 WW001 - Global Phase 2b AD Trial Design 1 Trial designed for dose-ranging, maximal efficacy and possible longer dosing interval (NCT04444752) A Randomized, Double-Blind, Placebo-Controlled Multi-Centered Trial of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of CBP-201 in Adult Sub
Slide 6: WW001 – Patient Disposition
6 6 WW001 – Patient Disposition 1,2 Greater active group discontinuations seen vs. dupilumab in phase 3 trials (SOLO1,2) Not a head-to-head trial. Differences exist between trial designs and subject characteristics and caution should be exercised when comparing data across trials 226 randomly assign
Slide 7: Baseline characteristics
WW001 - Baseline characteristics 7 7 Generally well balanced across treatment arms 1,2 Lower baseline median EASI vs. dupilumab in SOLO1,2 300 mg Q2W 150 mg Q2W 300 mg Q4W All CBP-201 Placebo All patients Characteristics* N=57 N=57 N=56 N=170 N=56 N=226 Age, years 39.6 ± 14.8 39.5 ± 16.0 41.7 ± 15.2
Slide 8: Efficacy Results - Primary Endpoint
WW001 – Efficacy Results - Primary Endpoint 8 8 EASI % Change from baseline (CFB) at Week 16 1 All doses of CBP-201 were statistically significant vs. Placebo, despite high placebo response CBP-201 WW001, LOCF, FAS % change in EASI at Week 16 0% -20% -40% -40.7% -60% -57.5%* -63.0%** -65.4%*** -80%
Slide 9: Efficacy Results – Key Secondary Endpoints
WW001 – Efficacy Results – Key Secondary Endpoints 9 9 % patients with IGA 0/1, and ≥2-point reduction / EASI-50, -75 or -90 % response vs. baseline at Week 16 1 CBP-201 300mg Q2W and Q4W delivered highest efficacy responses in the trial CBP-201 WW001, NRI, FAS CBP-201 WW001, NRI, FAS % IGA 0/1 resp
Slide 10: Efficacy Results – Key Secondary Endpoints: PP-NRS
WW001 – Efficacy Results – Key Secondary Endpoints 10 10 Change in weekly average PP-NRS at Week 16 1 CBP-201 300mg Q2W and Q4W delivered statistically significant improvements on itch; High placebo response CBP-201 WW001, LOCF, FAS Change in PP-NRS at Week 16 0 -1 -2 -2.26 -2.64 -3 -3.29* -3.56** -
Slide 11: WW001 - Safety Results
11 11 WW001 - Safety Results 1 Rates of conjunctivitis, injection site reaction, and herpes virus infections were low with CBP-201 CBP-201 300 mg CBP-201 150 mg CBP-201 300 mg All CBP-201 Placebo n (%) patients with… Q2W N=57 Q2W N=57 Q4W N=56 N=170 N=56 Any TEAE 26 (46%) 24 (42%) 32 (57%) 82 (48%)
Slide 12: WW001 – Understanding the Trial Population Recruited
12 12 WW001 – Understanding the Trial Population Recruited 1,2 WW001 and SOLO 1,2 recruited different patients and were conducted in different circumstances 1-4 • WW001 trial population recruited was different to that seen in SOLO 1,2 trials 3 1. Less severe disease as a result of • COVID-19 pandemi
Slide 13: WW001 – Additional Analyses
13 13 WW001 – Additional Analyses 1,2,3 Analyses of WW001 populations with disease severity more closely matched to SOLO 1,2 • Given differences in trial populations recruited, multiple analyses in WW001 were performed to determine the impact of baseline disease severity on the magnitude of treatmen
Slide 14: Key differences between enrolled patient populations
WW001 and SOLO 1,2 14 14 Key differences between enrolled patient populations 1,2,3 WW001 and SOLO 1,2 recruited different patients and were conducted in different circumstances Not a head-to-head trial. Differences exist between trial designs and subject characteristics and caution should be exerci
Slide 15: Analysis - China Subgroup Primary and Secondary Endpoints
WW001 – Analysis 1 - China Subgroup 15 15 Primary and Secondary Endpoints 1 CBP-201 300mg Q2W & Q4W placebo adjusted efficacy responses increased as disease severity increased CBP-201 WW001 [China subgroup], CBP-201 WW001 [China subgroup], CBP-201 WW001 [China subgroup], CBP-201 WW001 [China subgrou
Slide 16: Analysis - Median Results for Continuous Endpoints
WW001 – Analysis 2 - Median Results for Continuous Endpoints 16 16 EASI % CFB and PP-NRS CFB to Week 16 1 CBP-201 median placebo adjusted efficacy responses increased vs. LS means CBP-201 WW001, LOCF, FAS CBP-201 WW001, LOCF, FAS Median % change in EASI at Week 16 Median change in PP-NRS at Week 16
Slide 17: Analysis – EASI % CFB by baseline EASI tertiles
WW001 – Analysis 3 – EASI % CFB by baseline EASI tertiles 17 17 Post-hoc analysis 1 CBP-201 placebo adjusted efficacy responses increased with higher baseline EASI CBP-201 WW001, LOCF, FAS % change in EASI at Week 16 High EASI (>26.4) Low EASI (≤18.4) Mid EASI (>18.4–26.4) 0% 0% 0% -20% -20% -20% -4
Slide 18: Analysis – EASI % CFB by baseline TARC tertiles
WW001 – Analysis 4 – EASI % CFB by baseline TARC tertiles 18 18 Post-hoc analysis 1 CBP-201 placebo adjusted efficacy responses increased with higher baseline TARC^ CBP-201 WW001, LOCF, FAS % change in EASI at Week 16 High TARC (>291 pg/ml) Low TARC (≤116.74 pg/ml) Mid TARC (>116.74–291 pg/ml) 0% 0%
Slide 19: Efficacy Results – Primary & Additional Analyses: EASI
WW001 – Efficacy Results – Primary & Additional Analyses 19 19 Primary Endpoint - EASI % Change from baseline (CFB) to Week 16 1,2,3,4 CBP-201 300mg Q2W & Q4W efficacy responses appeared at least comparable to dupilumab For Illustrative Purposes Only:- Not a head-to-head trial. Differences exist bet
Slide 20: Efficacy Results - Secondary Endpoints: IGA 0,1
WW001 – Efficacy Results - Primary & Additional Analyses 20 20 Secondary Endpoints - IGA 0,1 % responders and EASI-50,-75,-90 % responders at Week 16 1,2,3 CBP-201 300mg Q2W & Q4W efficacy responses appeared at least comparable to dupilumab For Illustrative Purposes Only:- Not a head-to-head trial.
Slide 21: Efficacy Results - Secondary Endpoints: EASI-50,-75,-90
WW001 – Efficacy Results - Primary & Additional Analyses 21 21 Secondary Endpoints - EASI-50,-75,-90 % responders at Week 16 1,2,3 CBP-201 300mg Q2W & Q4W efficacy responses appeared at least comparable to dupilumab For Illustrative Purposes Only:- Not a head-to-head trial. Differences exist between
Slide 22: Efficacy Results - Secondary Endpoints: PP-NRS
WW001 – Efficacy Results - Primary & Additional Analyses 22 22 Secondary Endpoints - Change in weekly average PP-NRS at Week 16 1,2,3 CBP-201 300mg Q2W & Q4W efficacy responses appeared at least comparable to dupilumab For Illustrative Purposes Only:- Not a head-to-head trial. Differences exist betw
Slide 23: WW001 - Conclusions
23 23 WW001 - Conclusions WW001 Met Primary Endpoint & Key Secondary Endpoints; Phase 3 first patient enrolment estimated in 2H 2022 Not a head-to-head trial. Differences exist between trial designs and subject characteristics and caution should be exercised when comparing data across trials • CBP-2
Connect Biopharma Holdings — Technical Presentation (January 2022) on 6ix